UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways

Pharmacology & therapeutics (Oxford), 2016-02, Vol.158, p.71-90

2016

Volltextzugriff (PDF)

Targeting the fibroblast growth factor receptor family in cancer

Cancer treatment reviews, 2016-05, Vol.46, p.51-62

2016

Volltextzugriff (PDF)

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

Cancers, 2017-04, Vol.9 (4), p.38

2017

Volltextzugriff (PDF)

The role of DNA repair pathways in cisplatin resistant lung cancer

Cancer treatment reviews, 2014-12, Vol.40 (10), p.1161-1170

2014

Volltextzugriff (PDF)

Cancer survivors' experience of OptiMal, a 6-week, occupation-based, self-management intervention

The British journal of occupational therapy, 2019-02, Vol.82 (2), p.90-100

2019

Volltextzugriff (PDF)

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

The lancet respiratory medicine, 2017-05, Vol.5 (5), p.435-444

2017

Volltextzugriff (PDF)

The emerging role of microRNAs in resistance to lung cancer treatments

Cancer treatment reviews, 2015-02, Vol.41 (2), p.160-169

2015

Volltextzugriff (PDF)

Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.1213-1216

2018

Volltextzugriff (PDF)

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021-07, Vol.24 (4), p.970-977

2021

Volltextzugriff (PDF)

Feasibility Randomised Control Trial of OptiMal: A Self-Management Intervention for Cancer Survivors

Current oncology (Toronto), 2023-11, Vol.30 (12), p.10195-10210

2023

Volltextzugriff (PDF)

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1813-1821

2012

Volltextzugriff (PDF)

Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?

World journal of surgery, 2018-05, Vol.42 (5), p.1485-1495

2018

Volltextzugriff (PDF)

Second-Hand Smoke As a Predictor of Smoking Cessation Among Lung Cancer Survivors

Journal of clinical oncology, 2014-02, Vol.32 (6), p.564-570

2014

Volltextzugriff (PDF)

Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin

Translational oncology, 2021-04, Vol.14 (4), p.101025-101025, Article 101025

2021

Volltextzugriff (PDF)

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

Journal of thoracic oncology, 2016-11, Vol.11 (11), p.e142-e144

2016

Volltextzugriff (PDF)

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.416-425

2020

Volltextzugriff (PDF)

Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics

Journal of clinical oncology, 2010-09, Vol.28 (26), p.4029-4037

2010

Volltextzugriff (PDF)

Altered expression of ACOX2 in non-small cell lung cancer

BMC pulmonary medicine, 2022-08, Vol.22 (1), p.1-21, Article 321

2022

Volltextzugriff (PDF)

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines

Scientific reports, 2018-01, Vol.8 (1), p.1652-12, Article 1652

2018

Volltextzugriff (PDF)

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC

Cancer biology & therapy, 2014-10, Vol.15 (10), p.1367-1377

2014

Volltextzugriff (PDF)

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Clinical cancer research, 2017-05, Vol.23 (10), p.2460-2470

2017

Volltextzugriff (PDF)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC

Cancers, 2021-04, Vol.13 (9), p.2139

2021

Volltextzugriff (PDF)

An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)

Biomedicines, 2023-09, Vol.11 (9), p.2576

2023

Volltextzugriff (PDF)

USO1 expression is dysregulated in non-small cell lung cancer

Translational lung cancer research, 2022-09, Vol.11 (9), p.1877-1895

2022

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(126)

Publikationsform

Artikel
(126)
Tagungsberichte
(2)

Sprache

Englisch
(128)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(61)
Humans
(51)
Oncology
(46)
Male
(30)
Female
(28)
Aged
(26)
Middle Aged
(24)
Lung Neoplasms - Drug Therapy
(23)
Lung Cancer
(21)
Adult
(18)
Aged, 80 And Over
(18)
Respiratory System
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(16)
Chemotherapy
(16)
Cancer Therapies
(15)
Lung Neoplasms - Genetics
(15)
Patients
(14)
Tumors
(14)
Antineoplastic Agents - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways

Targeting the fibroblast growth factor receptor family in cancer

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

The role of DNA repair pathways in cisplatin resistant lung cancer

Cancer survivors' experience of OptiMal, a 6-week, occupation-based, self-management intervention

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

The emerging role of microRNAs in resistance to lung cancer treatments

Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Feasibility Randomised Control Trial of OptiMal: A Self-Management Intervention for Cancer Survivors

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada

Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?

Second-Hand Smoke As a Predictor of Smoking Cessation Among Lung Cancer Survivors

Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics

Altered expression of ACOX2 in non-small cell lung cancer

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC

An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)

USO1 expression is dysregulated in non-small cell lung cancer

Suchergebnisse filtern